Ardea Biosciences Awarded Composition of Matter Patent Covering RDEA806, Its Lead NNRTI for the Treatment of HIV
October 20 2008 - 8:00AM
Business Wire
Ardea Biosciences, Inc. (Nasdaq:RDEA) announced today that the
United States Patent and Trademark Office has issued a patent
covering the composition of matter of RDEA806, the Company�s lead
non-nucleoside reverse transcriptase inhibitor (NNRTI) for the
treatment of patients with human immunodeficiency virus (HIV), and
related analogs. U.S. Patent No.�7,435,752 was issued on
October�14, 2008. �We are very pleased with the continued expansion
of our proprietary position in the NNRTI area. This issued patent
significantly enhances the value of RDEA806 and strengthens our
ability to enter into future strategic alliances for its further
development,� commented Barry D. Quart, PharmD, Ardea�s president
and chief executive officer. �We look forward to further expanding
the proprietary position of RDEA806 and our other product
candidates through additional future patent issuances.� About
RDEA806 RDEA806 is a novel non-nucleoside reverse transcriptase
inhibitor (NNRTI) for the potential treatment of HIV infection.
Based on preclinical and clinical studies to-date, we believe that
RDEA806 may have important competitive advantages compared to
currently available NNRTIs. These include the potential for potent
antiviral activity against a wide range of HIV viral isolates,
including those that are resistant to Sustiva� (efavirenz) and
other currently available NNRTIs; a high genetic barrier to
resistance; no reproductive toxicity based on animal studies; the
potential to be administered in a patient-friendly, oral dosing
regimen; limited pharmacokinetic interactions with other drugs; and
the ability to be co-formulated with other HIV antiviral drugs.
About Ardea Biosciences, Inc. Ardea Biosciences, Inc., of San
Diego, California, is a biotechnology company focused on the
discovery and development of small-molecule therapeutics for the
treatment of HIV, gout, cancer and inflammatory diseases. We have
five product candidates in clinical trials and others in
preclinical development and discovery. Our most advanced product
candidate is RDEA806, a non-nucleoside reverse transcriptase
inhibitor (NNRTI), which has successfully completed a Phase 2a
study for the treatment of patients with HIV. We have evaluated our
second-generation NNRTI for the treatment of HIV, RDEA427, in a
human micro-dose pharmacokinetic study and have selected it for
clinical development. RDEA594, our lead product candidate for the
treatment of gout, is being evaluated in a Phase 1 clinical trial
and is believed to be an inhibitor of the URAT1 transporter in the
kidney, which is responsible for regulation of uric acid levels. We
are evaluating our lead MEK inhibitor, RDEA119, in a Phase 1/2
study in combination with Nexavar� (sorafenib) and as a single
agent in a Phase 1 study, both in advanced cancer patients, and
have completed a Phase 1 study in normal healthy volunteers as a
precursor to trials in patients with inflammatory diseases. Lastly,
we have evaluated our second-generation MEK inhibitor for the
treatment of cancer and inflammatory diseases, RDEA436, in a human
micro-dose pharmacokinetic study and have selected it for clinical
development. Statements contained in this press release regarding
matters that are not historical facts are "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995. Because such statements are subject to risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Such
statements include, but are not limited to, statements regarding
our goals, including the expected properties and benefits of
RDEA806, RDEA427, RDEA594, RDEA119, RDEA436 and our other compounds
and the results of preclinical, clinical and other studies. Risks
that contribute to the uncertain nature of the forward-looking
statements include: risks related to the outcome of preclinical and
clinical studies, risks related to regulatory approvals, delays in
commencement of preclinical and clinical studies, and costs
associated with our drug discovery and development programs and
business development activities. These and other risks and
uncertainties are described more fully in our most recently filed
SEC documents, including our Annual Report on Form 10-K and our
Quarterly Reports on Form 10-Q, under the headings "Risk Factors."
All forward-looking statements contained in this press release
speak only as of the date on which they were made. We undertake no
obligation to update such statements to reflect events that occur
or circumstances that exist after the date on which they were made.
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Ardea Biosciences, Inc. (MM) (NASDAQ:RDEA)
Historical Stock Chart
From Jul 2023 to Jul 2024